These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35154085)

  • 1. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
    Connell WT; Hong J; Liao W
    Front Immunol; 2021; 12():815121. PubMed ID: 35154085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
    van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
    JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
    Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
    Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
    Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
    J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
    Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
    Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
    Galluzzo M; D'Adamio S; Silvaggio D; Lombardo P; Massaro A; Egan CG; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2020 Jan; 20(1):95-104. PubMed ID: 31640431
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab for the treatment of psoriasis: an evidence update.
    Yiu ZZ; Warren RB
    Semin Cutan Med Surg; 2018 Sep; 37(3):143-147. PubMed ID: 30215630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.
    van Vugt LJ; van den Reek JMPA; Coenen MJH; de Jong EMGJ
    Br J Dermatol; 2018 Jan; 178(1):86-94. PubMed ID: 28646581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.